Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

MaineHealth aims to achieve American Society of Nuclear Cardiology (ASNC) guidelines with UltraSPECT technology

Healthcare system selects UltraSPECT nuclear medicine software for lowering dose and reducing exam time.

August 29, 2013

Exploring the M.O. of drug-resistant cancers

Researchers are forever seeking to outsmart therapy-resistant cancers. "No Through Road," a feature published Aug. 5 in Cancer Today, a publication of the American Association for Cancer Research, highlights just this quest.

August 27, 2013

Siemens Healthcare introduces continuous FlowMotion PET-CT

Siemens Healthcare has launched its new Biograph mCT Flow – a groundbreaking PET-CT system. For the first time ever the system overcomes the limitations of conventional bed-based PET-CT with FlowMotion, an innovative new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

August 22, 2013

Navidea awarded NIH SBIR grant for NAV4694 beta-amyloid imaging agent phase III clinical program aimed at Alzheimer’s disease

Navidea Biopharmaceuticals announces award of a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the National Institutes of Health (NIH) in connection with the Company's Phase 3 clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimer’s disease.

August 22, 2013

Navidea Biopharmaceuticals signs manufacturing agreement with Siemens’ PETNET Solutions for NAV4694 beta-amyloid imaging agent

Navidea has signed an agreement with Siemens’ PETNET Solutions that grants PETNET Solutions the right to manufacture Navidea’s Fluorine-18 labeled NAV4694, an investigational beta-amyloid PET imaging agent, which is currently being evaluated in Phase 2 and 3 clinical trials evaluating subjects with signs or symptoms of cognitive impairment such as Mild Cognitive Impairment and Alzheimer’s disease.

August 22, 2013

Siemens Healthcare introduces continuous FlowMotion PET-CT

Siemens Healthcare has launched its new BiographTM mCT Flow – a groundbreaking PET-CT system. For the first time ever the system overcomes the limitations of conventional bed-based PET-CT with FlowMotion, an innovative new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

August 20, 2013

RadNet Joins Partnership to Explore Potential Alzheimer's Disease Drug

RadNet Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 248 subsidiary-owned and/or operated outpatient imaging centers, announced its participation in a clinical trial to evaluate the biomarker effects of the investigational drug E2609, a BACE inhibitor, which is being developed for the potential disease modifying treatment of Alzheimer's disease (AD).

July 16, 2013

HHS Releases 2013 Update To The National Alzheimer's Plan

Today, the Department of Health and Human Services (HHS) released the National Plan to Address Alzheimer's Disease: 2013 Update. The first-ever National Alzheimer's Plan, initially released in May 2012, was mandated by the bipartisan National Alzheimer's Project Act (P.L. 111-375), which Congress passed unanimously in 2010. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer's disease by 2025 – and a review of progress over the past year.

June 17, 2013

Around the web

Automated AI-generated measurements combined with annotated CT images can improve treatment planning and help referring physicians and patients better understand their disease, explained Sarah Jane Rinehart, MD, director of cardiac imaging with Charleston Area Medical Center.

Two advanced algorithms—one for CAC scores and another for segmenting cardiac chamber volumes—outperformed radiologists when assessing low-dose chest CT scans. 

"Gen AI can help tackle repetitive tasks and provide insights into massive datasets, saving valuable time," Thomas Kurian, CEO of Google Cloud, said Tuesday. 

Trimed Popup
Trimed Popup